Filing Flows › Health Care › ArriVent BioPharma (AVBP)
ArriVent BioPharma (AVBP) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 9, 2026 · ArriVent BioPharma (AVBP) Q3 2026 earnings results →
Q3 2026 806¢ of every $1 of revenue lost · operating margin -867.5%
ArriVent BioPharma made $5.0M in Q3 2026. Operating margin -867.5%, net loss $40.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 9, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.0M in Q3 2026.
Operating costs exceeded revenue by $43.4M, an operating margin of -867.5%. The quarter ended with a net loss of $40.3M.
Operating cash flow was −$40.7M. Non-cash charges added back $6.9M of share-based compensation. Working capital and other items used $7.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 9, 2026 | $5.0M | — | -867.5% | −$40.3M | −$40.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About ArriVent BioPharma
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team’s deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 (MRG007), through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Firmonertinib is currently being evaluated in multiple clinical trials across a range of epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC).
In its own words, from its 10-K, filed Mar 5, 2026.
ArriVent BioPharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -867.5% against the peers' median 27.1%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AVBP ArriVent BioPharma | Q3 2026 | $5.0M | — | -867.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| SNY Sanofi | Q3 2026 | $16.6B | +16% | 30.1% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| AZN AstraZeneca | Q3 2026 | $16.2B | +7% | 27.1% |
| NVS Novartis AG | Q3 2026 | $14.5B | +4% | 12.7% |
Source: ArriVent BioPharma 10-Q on SEC EDGAR · CIK 1868279 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns AVBP and who is buying
More on AVBP
History
Every quarter: Q3 2026 results